You are here

Article Text

Article menu

Download PDFPDF

Late-Breaking Oral Abstracts
LB-007 Results of hybrid study, prospective randomized multicenter study of hydrogel coil vs bare platinum coil for intracranial aneurysms
Free
  1. N Sakai1,
  2. H Imamura1,
  3. C Sakai1,
  4. A Hyodo2,
  5. Y Ito3,
  6. Y Matsumaru4,
  7. S Miyachi5,
  8. S Yoshimura6,
  9. M Sasaki7,
  10. K Ogasawara8,
  11. S Miyamoto9,
  12. S Miyamoto9,
  13. M Ezura10,
  14. I Nakahara11,
  15. A Ishii9,
  16. T Higashi12
  1. 1Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan
  2. 2Neurosurgery, Dokkyo Medical Univesity Saitama Medical Center, Koshigaya, Japan
  3. 3Neurosurgery, Shinrakuen Hospital, Niigata, Japan
  4. 4Neurosurgery, Tsukuba University, Tsukuba, Japan
  5. 5Neurosurgery, Aichi Medical University, Nagakute, Japan
  6. 6Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan
  7. 7Radiology, Iwate Medical University, Morioka, Japan
  8. 8Neurosurgery, Iwate Medical Unuversity, Morioka, Japan
  9. 9Neurosurgery, Kyoto University, Kyoto, Japan
  10. 10Neurosurgery, Sendai Medical Center, Sendai, Japan
  11. 11Neurosurgery, Fujita Health University, Toyoake, Japan
  12. 12Neurosurgery, Fukuoka University Chikushi Hospital, Chikushino, Japan

Abstract

Purpose To present results of HYBRID study, whether second generation hydrogel coils (HGC) for the treatment of intracranial aneurysms improves outcomes compared with bare platinum coils.

Material and Methods HYBRID study is investigator-initiated, prospective, randomized, multicenter trial with open label treatment, blinded endpoint evaluation in Japan (NCT01516658). Inclusion criteria are 20–80 age, 7–20 mm size, unruptured or ruptured with WFNS grade I-III. For hydrogel coil arm (H group), recommended to use HGC 50% length or more with maximum effort and for bare platinum coil arm (B group) prohibited to use any HGC and surface modificated coil. Primary endpoint is recanalization, evaluated on DSA at 1-year after embolization, and late aneurysm rupture, re-treatment and adverse events are secondary endpoints.

Results 431 cases enrolled in 44 centers in Japan since March 2012 to March 2016, and completed last follow-up on March 2017. Background data, age, gender, aneurysm size, dome/neck ratio, VER were not significant different in both arms, and mean and median length% of used HGC was 68.6 and 69.9 in H Group and 1.2 and 0 in B Group. Primary endpoint in H group (3.3%, 7/214) couldn’t show significant difference (p=0.083) with that in B group (7.1%, 15/211). However, evaluation by same definition with previously published report, showed major recanalization at 1 year after procedure in H group (2.3%, 5/214) was significantly lower (p=0.039) than B group (6.6%, 14/211). And also, adverse event in H group is significantly lower than that in B group and no aneurysm rupture in both groups.

Conclusion Second generation hydrogel coils decreases adverse outcomes including recanalization and unfavorable clinical events in endovascular treatment for intracranial aneurysms.

Disclosures N. Sakai: 1; C; Terumo/Microvntion, Medtronic, Neurovasc, Daiichi-Sankyo. 2; C; Asahi Intec, Biomedical Solutions, Johnson&Johnson/Cerenovus, Medtronic, Neurovasc, Penumbra, Stryker, Terumo. H. Imamura: 2; C; Medtronic. C. Sakai: None. A. Hyodo: None. Y. Ito: None. Y. Matsumaru: None. S. Miyachi: None. S. Yoshimura: None. M. Sasaki: None. K. Ogasawara: None. S. Miyamoto: None. S. Miyamoto: None. M. Ezura: None. I. Nakahara: None. A. Ishii: None. T. Higashi: None.

http://dx.doi.org/10.1136/neurintsurg-2020-SNIS.279

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.